0E9EAAED-A9A2-41E7-AC3A-49E94C933432
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 1.1826544021024967
- age_years
- 72
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.655
- INFLAMMATORY_RESPONSE+0.605
- INTERFERON_GAMMA_RESPONSE+0.602
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.576
- COMPLEMENT+0.570
- ALLOGRAFT_REJECTION+0.568
- IL6_JAK_STAT3_SIGNALING+0.568
- INTERFERON_ALPHA_RESPONSE+0.567
- OXIDATIVE_PHOSPHORYLATION+0.558
- TNFA_SIGNALING_VIA_NFKB+0.520
Top 10 suppressed
- KRAS_SIGNALING_DN-0.305
- MITOTIC_SPINDLE-0.240
- SPERMATOGENESIS-0.192
- WNT_BETA_CATENIN_SIGNALING-0.067
- G2M_CHECKPOINT+0.041
- MYOGENESIS+0.075
- MYC_TARGETS_V2+0.080
- PANCREAS_BETA_CELLS+0.088
- BILE_ACID_METABOLISM+0.109
- HEDGEHOG_SIGNALING+0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 25C4D537-0142-4DAA-874B-BC793336DE82 | — | — | 0.971 |
| 2 | 53D8CF8D-31BA-4CB8-A14F-5C9AB9554F5D | — | — | 0.969 |
| 3 | 665044AD-F2DD-43C2-BCDE-982A8F5C5830 | — | — | 0.959 |
| 4 | 15FB165D-6751-4894-A904-C77EA723CFCB | — | — | 0.957 |
| 5 | BS_M8WP5T16 | low-grade glioma | — | 0.953 |
| 6 | A219A5D7-C67B-4CF0-860A-78ADEB56A13D | — | — | 0.951 |
| 7 | 0E5EDC5A-5AD4-499E-8777-CA6B6F63307F | — | — | 0.951 |
| 8 | 6727027F-4BAB-41ED-87F3-ECC7B1718ECF | — | — | 0.950 |
| 9 | 9BB56866-4E99-4E8A-A63F-2D4801558F14 | — | — | 0.949 |
| 10 | 5B9DEC62-3DC7-4DE2-8B20-3E191594FCB4 | — | — | 0.949 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 46 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.655 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.605 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.602 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.576 | Inavolisib | — uncovered |
| COMPLEMENT | 0.570 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.568 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.568 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.567 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.558 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| APOPTOSIS | 0.515 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.509 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.482 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.474 | Inavolisib | — uncovered |
| HYPOXIA | 0.448 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.448 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.443 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.437 | Idelalisib | — uncovered |
| COAGULATION | 0.418 | Binimetinib | — uncovered |
| UV_RESPONSE_UP | 0.386 | Idelalisib | — uncovered |